T Cell Activation Classification Using Autofluorescence Phasor Analysis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for determining T cell activation, such as flow cytometry and immunofluorescence imaging, require contrast agents and tissue fixation, making them unsuitable for use in treatments like CAR T cell therapy where labeled cells are needed.

Innovation Solution

A T cell classification device using a time-resolved autofluorescence decay spectrometer and phasor analysis to classify T cells based on their activation state without the need for contrast agents or fixation, employing a processor to compute phasor coordinates from autofluorescence decay signals.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If flow cytometry or immunofluorescence imaging is used to determine T cell activation, then activation state can be detected, but contrast agents and tissue fixation are required which make the cells unsuitable for subsequent therapeutic use

Engineering Contradiction:
ImproveT cell activation detection accuracyVSAvoidcell damage from fixation and labeling
Core Design Contradiction:
Measurement precisionVSObject-affected harmful factors

Solution Approach 1:

The patent utilizes the cell's own autofluorescence properties (NADH and FAD) as natural contrast agents to detect T cell activation state. By measuring the intrinsic fluorescence of metabolic cofactors that change during activation, the system eliminates the need for external fluorescent labels and fixation procedures, thereby preserving cell viability for subsequent therapeutic applications

Inventive Principle:
Principle #25Self-service

Solution Approach 2:

The patent detects T cell activation by monitoring changes in the fluorescence lifetime parameters of endogenous metabolites NADH and FAD. As T cells activate, their metabolic state changes, altering the fluorescence decay characteristics of these cofactors. This parameter-based detection method provides activation information without requiring physical or chemical modification of the cells

Inventive Principle:
Principle #35Parameter changes

2Reliability

If time-resolved autofluorescence decay measurement is used, then cell viability is preserved for therapy, but the measurement system becomes more complex

Engineering Contradiction:
Improvecell suitability for CAR T therapyVSAvoidtime-resolved spectrometer system
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent transitions from measuring steady-state fluorescence intensity to measuring fluorescence decay over time (adding the time dimension). By resolving the temporal profile of autofluorescence decay, the system can distinguish between different metabolic states of T cells based on the characteristic lifetime signatures of NADH and FAD, providing more information without requiring additional labels or complex sample preparation

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

3Measurement precision

If multiple frequencies are used for phasor analysis, then classification precision improves, but computational requirements increase

Engineering Contradiction:
ImproveT cell activation classification accuracyVSAvoidcomputational processing power
Core Design Contradiction:
Measurement precisionVSPower

Solution Approach 1:

The patent calculates phasor coordinates at multiple frequency points (including the excitation frequency and its harmonics) to improve classification accuracy. By sampling the fluorescence decay signal at several discrete frequencies and converting to phasor space, the system creates a more robust signature for distinguishing activated from resting T cells, with the computational cost justified by the significant improvement in classification precision

Inventive Principle:
Principle #16Partial or excessive action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables accurate classification of T cells with high precision, allowing for the enrichment of activated T cells for treatments like CAR T cell therapy, while avoiding the use of fluorescent labels and fixation.

Implementation Method 1

acquire a time-resolved autofluorescence decay signal for a T cell positioned in the observation zone

Methodology Applied
Scientific EffectAutofluorescence: Fluorescence

Implementation Method 2

The time-resolved autofluorescence decay spectrometer is configured to acquire a time-resolved autofluorescence decay signal

Methodology Applied
Scientific EffectTime-resolved fluorescence decay: Fluorescence

Data Source

PatentUS12502671B2Systems and methods for classifying T cell activation state
Publication Date: 2025.12.23 WISCONSIN ALUMNI RES FOUND
  • US12502671B2 patent drawing
  • US12502671B2 patent drawing
  • US12502671B2 patent drawing

AI summary

Systems and methods for classifying T cells by activation state are disclosed. The system includes a cell analysis pathway, a time-resolved autofluorescence decay spectrometer, a processor, and a non-transitory computer-readable memory. The memory is accessible to the processor and has stored thereon instructions. The instructions, when executed by the processor, cause the processor to: a) receive the time-resolved autofluorescence decay signal; b) compute at least a first phasor coordinate at a first frequency and a second phasor coordinate at a second frequency from the time-resolved autofluorescence decay signal, wherein the first and second frequency are different; and c) compute an activation prediction for the T cell using at least the first phasor coordinate and the second phasor coordinate.